Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва ФГБУ Московский НИИ психиатрии Минздрава России
Список исп. литературыСкрыть список 1. Лисицына Т.А., Зелтынь А.Е., Вельтищев Д.Ю. и др. Расстройства тревожно-депрессивного спектра и когнитивные нарушения у больных ревматоидным артритом. Неврол. и психиатр. 2012; 112 (11): 96–104. 2. Лисицына Т.А., Вельтищев Д.Ю., Насонов Е.Л. Стрессовые факторы и депрессивные расстройства при ревматических заболеваниях. Научно-практич. ревматология. 2013; 2: 98–103. 3. Марченко А.С., Серавина О.Ф., Ковалевская О.Б. и др. Аффективно-стрессовая модель депрессии: практическое внедрение в ревматологической практике. Психиатр. и психофармакотер. 2009; 5: 17–21. 4. Мосолов С.Н. Фармакотерапия психических расстройств. В кн.: Психиатрия. Под ред. А.Г.Гофмана. М.: Медпресс, 2006; с. 377–438. 5. Bot M, Carney RM, Freedland KE et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. J Psychosom Res 2011; 71 (1): 13–7. 6. Brunoni AR, Machado-Vieira R, Zarate C, Valiengo L. Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation: results from a factorial, randomized controlled trial. Psychopharmacol 2013; 1. 7. Burns A, Russel E, Stratton-Powell H. Sertraline in stroke-assocatedlability of mood. Int J Geriat Psychiat 1999; 14: 681–6. 8. Dike GL. Triphasic waves in serotonin syndrome. J Neurol Neurosurg Psychiat 1997; 62: 200. 9. Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiat 1988; 49 (Suppl.): 46–51. 10. Doogan DP. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharm 1991; 6 (Suppl.): 2: 47–56. 11. Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of derpression in symptomatic HIV infection and AIDS. Improvement of affective and somatic symptoms. Gen Hosp Psychiat 1997; 19: 89–97. 12. Goldberg D. Prescribing antidepressants in primary care and hospital practice. WPA Bull on Depression 2003; 7 (26): 3–6. 13. Goodnick PJ, Kumar A, Henry JH. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997; 33: 261–4. 14. Goodnik PJ, Goldstein BJ. Selective serotonine reuptake inhibitors in affective disorders. J Basic Pharmacol 1998; 12: 5–20. 15. Hauser RA. Zesievicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov Dis 1997; 12: 756–9. 16. Hyttel J. Comparative pharmacological studies of selective serotonine reuptake inhibitors (SSRIs). Nord J Psychiat 1993; 47 (Suppl.) 30: 5–20. 17. Janssen В, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol Clin Exp 2010; 25: 201–15. 18. Khouzam HR, Emes R, Gill T, Raroque R. The antidepressant sertraline: a review of its uses in a range of psychiatric and medical conditions. Compr Ther 2003; 29 (1): 47–53. 19. Lisitsyna TA, Veltishchev D, Seravina O et al. Depression recovery improves the efficacy of rheumatoid arthritis treatment. Ann Rheumat Dis 2013; 72 (Suppl. 3): 610. SAT0090. 20. Lustman PJ, Clouse R, Nix B, Freedland K., Rubin E., McGill J., Williams M. Sertraline for prevention of depression recurrence in diabetes mellitus. Arch Gen Psychiat 2006; 63: 521–9. 21. Malhi GS, Berk M. Does dopamine dysfunction drive depression? Acta Psychiat Scand 2007; 115 (Suppl. 433): 116–24. 22. MaqQueen G, Born L, Steiner L. The selective reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev 2001; 1: 1–24. 23. McDougle CJ, Brodkin ES, Naylor ST. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998; 18: 62–6. 24. Parissis J, Fountoulaki K, Paraskevaidis I, Kremastinos D. Sertraline for the treatment of depression in coronary disease and heart failure. Exp Opin Pharmacother 2007; 8 (10): 1529–37. 25. Pizzi C, Mancini S, Angeloni L et al. Effects of selective serotonine reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther 2009; 86 (5): 527–32. 26. Ramen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggression in Huntington’s disease. J Neuropsychiat Clin Neurosciense 1996; 8: 338–40. 27. Sansone R, Sansone L. Warfarin and antidepressants. Psychiat 2009; 6 (7): 24–9. 28. Scott TF, Nussbaum P, McConnell H, Brill P. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res 1995; 17: 421–2. 29. Serebruany VL, Suckow RF, Cooper TB et al: Relationship Between Release of Platelet/Endothelial Biomarkers and Plasma Levels of Sertraline and N-Desmethylsertraline in Acute Coronary Syndrome Patients Receiving SSRI Treatment for Depression. Am J Psychiat 2005; 162: 1165–70. 30. Slaughter JR, Parker JC, Martens MP et al. Clinical Outcomes Following a Trial of Sertraline in Rheumatoid Arthritis. Psychosomatics 2002; 43: 36–41. 31. Stahl SM. The sigma-enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiat 2008; 69 (11): 1673–4. 32. Sutcigil L, Oktenly C, Musabak U, Bozkurt A. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Develop Immunol 2007; 4: 50–61. 33. Taler M, Gil-Ad I, Lomnitski L et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol 2007; 17 (12): 774–80. 34. Taylor CB, Youngblood M, Catellier D, Veith R et al. Effacts of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiat 2005; 62: 792–8. 35. Wozniak G, Toska A, Saridi M, Mouzas O. Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit 2011; 17 (9): 205–14.